

Rheumatology Workforce in Canada

By Claire Barber, MD, PhD, FRCPC

The Arthritis Alliance of Canada's System Level Performance Measures were designed to evaluate models of care to ensure patients with inflammatory arthritis receive timely diagnosis and treatment. Central to ensuring timely care is making sure there are adequate numbers of rheumatologists for making an early diagnosis and starting appropriate treatment.

In 2015, the Canadian Rheumatology Association launched "Stand Up and Be Counted," a national workforce survey of rheumatologists across Canada. The results highlighted that there is a current shortage of rheumatologists across the country that may worsen over the next 10 years because a third of the workforce reported plans to retire in the near future.

Further analysis of the results of the survey will be published imminently in *The Journal of Clinical Rheumatology* and will describe factors associated with rheumatologists' clinical work hours and patient volumes.

Dr. Claire Barber, Assistant Professor, Rheumatologist, University of Calgary, Calgary, AB

Reference:
Barber CEH, et al. Stand Up and Be Counted: Measuring and Mapping the Rheumatology Workforce in Canada. *J Rheumatol* 2017; 44(2):248-57.




Figure 1. Distribution of Rheumatologists Across Canada

Map of Canada showing the number of FTE-practicing rheumatologists per 75,000 population and the number of FTE rheumatologists required to meet the target of 1:75,000 benchmark (superimposed provincial count). FTE were estimated based on the national median reported time allocated to clinics from all respondents of the 2015 Stand Up and Be Counted survey and used to adjust the 2015 Canadian Medical Association numbers of rheumatologists in each province.

Reprinted with permission from *The Journal of Rheumatology*, Barber, C.E.H. et al, *J Rheumatol* 2017; 44(2). All rights reserved.

Economic Perspectives

By Elena Lopatina, MD, MSc; Deborah A. Marshall, PhD; Vandana Ahluwalia, MD, FRCPC; Stephanie Garner, MD, MSc; Hani El-Gabalawy, MD, FRCPC, FCAHS; Dianne Mosher, MD, FRCPC; and Carter Thorne, MD, FRCPC

The devastating consequences of inflammatory arthritis (IA) to individual patients and the healthcare system burden associated with the treatment of IA and productivity losses^{1,2} highlight the need to provide the right care to the right patient at the right time.³

Given the scarcity of healthcare resources and financial constraints,⁴ the efficiency of care (*i.e.*, optimal use of resources in achieving desired outcomes⁵) is an important aspect to consider.⁵⁻⁷ Models of care (MOCs) are one approach that is expected to improve accessibility, appropriateness, effectiveness, and safety of care for IA patients⁸ and, consequently, to improve patient outcomes and increase likelihood of remission⁹ and reduce the associated medical costs.¹⁰⁻¹⁵

From an economic perspective, there may be costs associated with the implementation and operation of MOCs (*e.g.*, education and training of staff, ongoing funding for staff salaries), but this must be balanced against the benefits to patients in terms of improved outcomes and reduced health care costs associated with the management of patients with IA with lower disease activity. MOCs for IA patients thus have the potential to be cost-effective and possibly cost-saving.

The current evidence regarding the efficiency of MOCs for IA patients is limited, especially in local Canadian settings. To draw decision-makers' attention to and improve uptake of MOCs for arthritis patients, evidence on their efficiency is required. The Arthritis Alliance of Canada (AAC) is currently undertaking a cost consequences analysis of MOCs

for IA patients with a specific focus on the access to care element of MOCs for IA patients to demonstrate the benefits of implementing MOCs and explore their efficiency.

Dr. Elena Lopatina, PhD candidate, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB

Dr. Deborah A. Marshall, Professor, Department of Community Health Sciences Cumming School of Medicine, University of Calgary, Calgary, AB

Dr. Vandana Ahluwalia, former Corporate Chief of Rheumatology, William Osler Health System, Brampton, ON

Dr. Stephanie Garner, MD, MSc, Rheumatology PGY4, McMaster University, Hamilton, ON

Dr. Hani El-Gabalawy, Professor of Medicine and Immunology; Endowed Rheumatology Research Chair, University of Manitoba, Winnipeg, MB

Dr. Dianne Mosher, Professor of Medicine, Division Head, Rheumatology, University of Calgary, Calgary, AB

Dr. Carter Thorne, Rheumatologist/Medical Director, The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON

References:

1. Marshall DA, Jonsson E, Martin L, et al. Rheumatoid arthritis in a policy perspective. A registry for research and better treatment of Albertans. Institute of Health Economics. 2015.
2. Bombardier C, Hawker G, Mosher D. The impact of arthritis in Canada: today and over the next 30 years. Arthritis Alliance of Canada 2011. Available at arthritisalliance.ca/images/PDF/eng/Initiatives/20111022_2200_impact_of_arthritis.pdf. Accessed March 12, 2018.
3. Epping-Jordan J, Pruitt S, Bengoa R, et al. Improving the quality of health care for chronic conditions. *Qual Saf Health Care* 2004; 13(4):299-305.
4. Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes: Oxford University Press; 2015.
5. Alberta Quality Matrix for Health. Health Quality Council of Alberta; 2005.
6. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. *Health Affairs* 2008; 27(3):759-69.
7. Crossing the quality chasm: a new health system for the 21st century. National Academy Press; 2001. Report No.: 0309073227.
8. Garner S, Lopatina E, Rankin JA, et al. Nurse-led care for patients with rheumatoid arthritis: a systematic review of the effect on quality of care. *J Rheumatol* 2017; 44(6):757-65.
9. Gwinnett JM, Symmons DP, MacGregor AJ, et al. The 20-year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: results from the Norfolk Arthritis Register. *Arthritis Rheumatol* 2017; 69(8):1566-75.
10. Barnabe C, Thanh NX, Ohinmaa A, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. *Ann Rheum Dis* 2013; 72(10):1664-8.
11. Beresniak A, Gossec L, Goupille P, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. *J Rheumatol* 2011; 38(3):439-45.
12. Huscher D, Mittendorf T, von Hinüber U, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. *Ann Rheum Dis* 2015; 74(4):738-45.
13. Ahluwalia V, Frank C, Mosher D, et al. A pan-Canadian approach to inflammatory arthritis models of care. Arthritis Alliance of Canada 2014. www.arthritisalliance.ca.

Advocating for Change

By Kelly Lendvoy; and Janet Yale

This special issue of *The Canadian Rheumatology Association Journal* has been dedicated to highlighting the many projects and initiatives that have been undertaken by the Arthritis Alliance of Canada (AAC) and the rheumatology community in the last five years. These initiatives have also formed the basis for our advocacy efforts with policymakers across the country whose decisions today will impact patients' access to quality arthritis care in the years to come.

Our advocacy and awareness goals are to ensure arthritis is fully understood by our key external audiences, such as health care providers, government, employers and private health insurers, and compel them to engage and invest in our community's initiatives. To accomplish these goals, the AAC mobilizes and activates our members, providing them the tools and data to tell the arthritis story.

The AAC has developed guidelines to ensure our advocacy activities are effective and sustainable:

- Integrated with AAC awareness raising;
- Scaled to its capacity and resources;
- Opportunistic and leveraging the current political or policy environment;

- Appealing and relevant to its supporters and members; and
- Offering an opportunity to build government relations capacity of the organization and advocacy interest of AAC supporters and members.

As we move forward, the AAC will continue to leverage the wide range of expertise, capabilities and networks of its members from across Canada to provide evidence-based information to inform and support policies that improve the delivery of care to people with arthritis. Their ongoing work, both as individual organizations and in collaboration with other arthritis stakeholders, is essential to achieving the overall goals of mitigating the personal and societal burden of the more than 100 types of arthritis—the leading cause of pain and disability in Canada.

Mr. Kelly Lendvoy, Vice President, Communications and Public Affairs, Arthritis Consumer Experts, Vancouver, BC

Ms. Janet Yale, Chair of Board, Arthritis Alliance of Canada; President & Chief Executive Officer, Arthritis Society, Toronto, ON